VM

Vincent Miles

Executive Director at Abingworth

Boston, Massachusetts

Invests in

Stages:

  • Min Investment:

    $15,000,000.00
  • Max Investment:

    $30,000,000.00
  • Target Investment:

    $22,500,000.00

Skills

R&D
Business Development
Commercialization
Technology Transfer
Start-ups
Biology
Licensing
Corporate Development
Competitive Analysis
Venture Capital
Mergers
Lifesciences
Biotechnology
Due Diligence
Entrepreneurship
Pharmaceutical Industry
Strategic Planning
Oncology
Business Planning
Business Strategy

Education

  • B.Sc. (biochemistry), Ph.D. (biochemical embryology/molecular biology)

    (1969 - 1975)

Work Experience

  • Executive Director

    2022

  • Partner

    2007 - 2022

    Representing Abingworth, have served on the Boards of Chiasma, Dicerna Pharmaceuticals, Dynex Technologies, Hydra Biosciences, IFM Therapeutics, IFM Due, IFM Tre, IFM Quattro, Magellan Diagnostics, Personalis and PrimeraDx, and as a Board observer at Atsena Therapeutics and Nido Biosciences. Abingworth is a life-sciences venture capital firm that invests mainly in companies discovering and developing novel therapeutics for unmet clinical needs.

  • Senior VP, Business Development

    2003 - 2007

  • VP, Business Development, Technology Management

    1997 - 2003

  • Director, Office of Technology Transfer

    1996 - 1997

RiboGene (a predecessor of Questcor)

1992 - 1996

  • VP, R&D and Business Development

    1992 - 1996

1986 - 1992

  • VP, International Marketing (Molecular Biology Division)

    1989 - 1992

  • VP, R&D (Molecular Biology Division)

    1986 - 1990

Amersham International

1978 - 1986

  • R&D and Business Development

    1978 - 1986

Home Office Forensic Science Laboratory

1975 - 1978

  • Higher Scientific Officer

    1975 - 1978